WPD Pharmaceuticals Logo
CA92941F1053
A2PX9R
WBIO.CN

WPD Pharmaceuticals

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, WPD Pharmaceuticals had revenue of €0 and net profit of -€54.67K
(EUR) 2023
YoY
Revenue 0 -
Gross profit 0 100.00%
Net profit -54.67K 102.06%
EBITDA -23.29K 100.84%

Fundamentals

Metric Value
Market capitalization
€206.43K
Number of shares
4.64M
52-week high/low
€0.72 - €0.0445
Dividends No
Beta
0.17
P/E ratio
-100.00
PEG ratio
1.02
P/B ratio
-14.28
P/S ratio
0.00

Company profile

WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Name
WPD Pharmaceuticals
CEO
Mariusz Olejniczak
Headquarters Vancouver, bc
Poland
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
01/13/2020
Employees 16

Ticker symbols

Exchange Symbol
Cnq
WBIO.CN
Pnk
WPDPF
Hamburg
8SV1.HM
München
8SV1.MU
🍪

Parqet  uses cookies. Learn more